Genetic Technologies Limited (ASX: $GTG) Public Offering Overview

Genetic Technologies Limited (ASX: $GTG) is offering 16,800,000 ordinary shares represented by 560,000 American Depositary Shares (ADSs) at an offering price of $2.00 per ADS. Additionally, pre-funded warrants to purchase up to 13,200,000 ordinary shares represented by 440,000 ADSs are being offered at an offering price of $1.999 per pre-funded warrant. The company is also conducting a concurrent private placement to sell unregistered warrants to purchase up to 30,000,000 ordinary shares represented by 1,000,000 ADSs at an initial exercise price of $2.00 per ADS. The net proceeds from the offering will be used for driving revenue, supporting sales and marketing initiatives, expanding into new markets, funding product research and development, and for other working capital and general corporate purposes.

Executive Commentary on Public Offering

The company is pleased to announce the public offering, which will provide the necessary capital to drive revenue, expand into new markets, and support the launch of our comprehensive risk assessment test. This offering represents a significant step in our strategic plan to further establish Genetic Technologies as a global leader in genomics-based tests for health, wellness, and serious diseases.

Summary of Genetic Technologies Public Offering

Genetic Technologies Limited (GTG) plans to use the net proceeds from its offering for various purposes, including driving revenue and supporting sales and marketing initiatives, expanding into new markets, executing sales and marketing for launching a comprehensive hereditary breast and ovarian cancer risk test, funding product research and development, and other working capital and general corporate purposes. The company also plans to sell 16,800,000 ordinary shares represented by 560,000 ADSs and pre-funded warrants to purchase up to 13,200,000 ordinary shares represented by 440,000 ADSs. Additionally, in a concurrent private placement, GTG is selling unregistered warrants to purchase up to 30,000,000 ordinary shares represented by 1,000,000 ADSs at an exercise price of $2.00 per ADS. The company also discusses the potential impact of volatile economic or business conditions on its operations.